Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.
Autor: | Shi D; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Chen J; Department of Infectious Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zhao M; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China., Tang Y; Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China., Zhao C; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Jin Y; Liver Disease Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Tian D; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Liao Y; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Wang X; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Wang W; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Fan X; Department of Respiratory Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China., Yi Z; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. zgyi@fudan.edu.cn.; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China. zgyi@fudan.edu.cn., Chen X; Department of Infectious Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. chenxiaohua2000@163.com., Ling Y; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. yun.ling@shphc.org.cn.; Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. yun.ling@shphc.org.cn. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of clinical immunology [J Clin Immunol] 2024 Mar 10; Vol. 44 (3), pp. 80. Date of Electronic Publication: 2024 Mar 10. |
DOI: | 10.1007/s10875-024-01683-z |
Abstrakt: | Objective: We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2. Methods: Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted. Results: In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts. Conclusion: The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |